If you are wondering whether Pfizer's current share price offers value for what you are getting, this article breaks down the ...

At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

Now, it’s worth noting Stock Advisor’s total average return is 971 % — a market-crushing outperformance compared to 196% for ...

Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...

Explore the exciting world of Pfizer (NYSE: PFE) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer PFE has announced that it is discontinuing development of its oral small molecule GLP-1 agonist, danuglipron, after one patient in a clinical trial experienced a liver injury that could have ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...

Times of crisis often reveal the character of leaders. "I'm very optimistic," said Bourla, who goes with a "nothing is impossible" mindset. "If there is something about me as a leader ... it is my ...